Bremer Trust National Association’s Corcept Therapeutics CORT Stock Holding History

Bremer Trust National Association’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	$54K	Buy	+4,015	New	+$53.1K	0.01%	434

Other funds holding CORT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bremer Trust National Association's CORT Position: Q4 2018 in Review

Bremer Trust National Association opened a new position in Corcept Therapeutics (CORT) in Q4 2018: 4,015 shares worth $54K. The stake represents 0.01% of the portfolio and ranks #434 among its holdings.

222 funds tracked by Wall St. Rank hold CORT as of Q4 2018.

Bremer Trust National Association held 4,015 shares of Corcept Therapeutics worth $54K as of Q4 2018.
Corcept Therapeutics was a new Bremer Trust National Association position in Q4 2018.
Corcept Therapeutics made up 0.01% of Bremer Trust National Association's portfolio in Q4 2018, its #434 holding.
222 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q4 2018.

Based on Bremer Trust National Association's 13F filing for Q4 2018, filed 11 Feb 2019.